News
WILLOW (NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results